Lilly completes its acquisition of Centessa Pharmaceuticals

Lilly completed its acquisition of Centessa Pharmaceuticals on June 24, 2026, when the UK court order took effect under a scheme of arrangement. Centessa shareholders received $38 per share in cash plus one contingent value right paying up to $9 per share. Centessa became a wholly owned Lilly subsidiary and was moved to delist from Nasdaq.

• Cash consideration $38.00 per share
• CVR worth up to $9.00 per share in aggregate
• Court order delivered to the Registrar on June 24, 2026